Evercore Inc.
EVREvercore Inc. (EVR) is a global independent investment banking advisory firm that provides strategic, financial, and merger and acquisition advice to corporations, financial sponsors, and institutional clients. Founded in 1995, the company is known for its expertise in mergers and acquisitions, restructuring, and capital raising, offering comprehensive advisory services without affiliated underwriting businesses. Its reputation is built on independent advice, deep industry expertise, and a client-focused approach.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 12, 2026 | $0.89 | 2026-05-29 | 2026-05-29 |
| March 13, 2026 | $0.84 | 2026-02-27 | 2026-02-27 |
| December 12, 2025 | $0.84 | 2025-11-28 | 2025-11-28 |
| September 12, 2025 | $0.84 | 2025-08-29 | 2025-08-29 |
| June 13, 2025 | $0.84 | 2025-05-30 | 2025-05-30 |
Dividends Summary
- Consistent Payer: Evercore Inc. has rewarded shareholders with 78 dividend payments over the past 19 years.
- Total Returned Value: Investors who held EVR shares during this period received a total of $32.56 per share in dividend income.
- Latest Payout: The most recent dividend of $0.89/share was paid 36 days ago, on June 12, 2026.
- Yield & Schedule: EVR currently pays dividends quarterly with an annual yield of 1.00%.
- Dividend Growth: Since 2007, the dividend payout has grown by 1171.4%, from $0.07 to $0.89.
- Dividend Reliability: EVR has maintained or increased its dividend for 78 consecutive payments.
Company News
Sandisk shares dropped 12.54% on Monday amid a broader chip stock pullback. However, major Wall Street analysts remain bullish, with Goldman Sachs raising its price target to $2,200 and Evercore lifting its target to $3,100. Both analysts cite sustained AI-driven demand for memory chips from data center operators as justification for their optimi...
Hemab Therapeutics Holdings, Inc., a clinical-stage biotechnology company focused on blood coagulation disorder treatments, priced its initial public offering at $18.00 per share for 16.75 million shares, raising approximately $301.5 million in gross proceeds. The company's stock is expected to begin trading on Nasdaq under ticker symbol 'COAG' o...
BofA Securities initiated coverage of Evercore (NYSE:EVR) with a Buy rating and $435 price target, calling it the 'best pure-play among boutique investment banks.' The analyst highlights Evercore's high advisory revenue mix (80% of total), strong M&A expertise, and growth potential from franchise expansion. With M&A activity expected to reach rec...
ProQR Therapeutics will participate in the 8th Annual Evercore Healthcare Conference, presenting its Axiomer™ RNA editing technology platform that enables targeted single nucleotide changes in RNA to potentially develop new disease treatments.
Madrigal Pharmaceuticals will participate in three upcoming healthcare investor conferences in November and December 2025, presenting live webcasts about their MASH treatment Rezdiffra.
